TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Critical tumor/breast volume ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pancreatic Fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of a first VAP episode
Endpoint domain: Adverse events/effects
Primary endpoint: Capsaicin-induced hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Controlled disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCD severity (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in probing bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in loss of clinical insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scalp microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amylase and Lipase Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anastomotic leakage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesia efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Any Protocol-Defined Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Infusion Related Reactions (IRRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in knowledge about medication abortion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Constant Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differences in reactions to problem behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differences in satisfaction with social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Diabetes summary quality measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in ADAS-Cog14 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accommodation process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinically detectable hernias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Pressure Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with invasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in albumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in fall incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life as measured by Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life as measured by Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life as measured by EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life as measured by Scoliosis Research Society (SRS) Form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life as measured by Lumbar Stiffness Disability Index (LSDI) Form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hs-CRP (high-sensitivity C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in HIV associated neurocognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of General Practitioner in performing CUS for the diagnosis of DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vitamin D 25 OH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of subjects with no vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prothrombin Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated Cephalin Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinogen level and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ClassIntra grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement accuracy of IMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluation: paucity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in numbers of platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response at Week 12 as Assessed by CDAI or RAPID3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving Low Disease Activity at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in QOL-B Respiratory Symptoms Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of >= grade 2 gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of >= grade 2 genitourinary toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total dose of glucocorticoids used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in PTB rate
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: White Blood Cell Count Elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: oral health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Blood Products Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Identification of acetylation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Usefulness of the Application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with the mutation for acute myelogenous leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Day number to functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: days of hospitalization after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Serum 25-hydroxyvitamin D (25OHD) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in parathyroid hormone (PTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: skeletal muscle size of biceps brachii and quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to Intervention Once an ADE Alert Has Fired
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)
Endpoint domain: Adverse events/effects
Primary endpoint: Antidepressant Side Effect Checklist (ASEC)
Endpoint domain: Adverse events/effects
Primary endpoint: Log Change From Baseline in BCR-ABL Transcript Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splenic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change in perception of recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exact and ±1 agreement to compared device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of calcified aortic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in attitudes towards LGBT patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in knowledge for LGBT competent practice
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in clinical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life after 6 months of education
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in amplitude of motor evoked potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in atrial fibrillation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean QTcF/QTcB change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of pregnant women experiencing changes in QT, QTcF and QTcB measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial plasma GLP-1 area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Very good partial response or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAK expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma Volume (PV) Pre-dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Volume (PV) Post-dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial Volume (ISV) Pre-dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial Volume (ISV) Post-dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Reporting Any Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Reporting Any Treatment-emergent Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of infants achieving clinically-relevant reduction in crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants reported with absence of 'colic'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of Urinary Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CLASI activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical cytology abnormal cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Aerosol deposition in pulmonary compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immunologic anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post PCI coronary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post PCI coronary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of program participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Frequency of Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of NF-kB Target Transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of Drug Efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival to 28 days without proven fungal infection
Endpoint domain: Mortality/survival
Primary endpoint: Mean variation in BP at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Yale - Brown Obsessive Compulsive Scale (Y-BOCS) Absolute Change From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VO2max Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain Clinical response at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Oswestry Disability Index (ODI) measure at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breast cancer free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Upper Extremity Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wake time after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Estimation of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gestuality frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gestuality duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Intramuscular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chimiokine MCP1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-H7N3 antibody titer
Endpoint domain: Physiological/clinical
Primary endpoint: Amount of vaccine virus shed
Endpoint domain: Physiological/clinical
Primary endpoint: Accuracy of USPIO MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intravascular central catheter colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation coefficient for paired measurements of PVP and CVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Mirena users with Amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence rate of Amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bronchiolitis Severity Score grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intracerebral hematoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with normalized liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Target location accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ABPM measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achieving good metabolic control of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of unplanned readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adequacy of final working length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Percent Inhibition Platelet Reactivity Unit (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to complete insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the steady-state plasma concentrations of TMC649128
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load decreases and/or changes of viral load from baseline (HCV RNA copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of PCR-confirmed rotavirus severe gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Majeed Pelvic Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SMFA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak plasma concentration of Dihydroartemisinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve of Dihydroartemisinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of Piperaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve of Piperaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Health Education Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety Blood Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: academic results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Epworth sleepiness scale from baseline
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in simple reaction time from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of painful days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Subjective physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device-measured physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Emactuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by Visual Analog Scales (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reproductive hormone measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: efficacy of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EpiCheck result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Platelet Count >=50 Gi/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of joint bleeds per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor Pressure at Maximum Flow Rate (PdetQmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes